Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Shepherd

Showing results (681-690 of 726) with videos related to

Pageof 73
Sort By:
JNCI Cancer Spectrum|September 6, 2021
Cancer Antigen 15-3/Mucin 1 Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs PlaceboPamela J Goodwin, Ryan J O Dowling, Marguerite Ennis, et al.
AIDS (London, England)|August 9, 2013
Higher rates of AIDS during the first year of antiretroviral therapy among migrants: the importance of tuberculosis, Bryan E Shepherd, Cathy A Jenkins, et al.
The Journal of Biological Chemistry|June 13, 2014
Insight into the architecture of the NuRD complex: structure of the RbAp48-MTA1 subcomplexSaad S M Alqarni, Andal Murthy, Wei Zhang, et al.
Journal of the International AIDS Society|March 22, 2016
Health outcomes among HIV-positive Latinos initiating antiretroviral therapy in North America versus Central and South AmericaCarina Cesar, John R Koethe, Mark J Giganti, et al.
Journal of the National Cancer Institute|July 2, 2013
Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarkerDennis C Sgroi, Erin Carney, Elizabeth Zarrella, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2012
Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trialMaggie C U Cheang, K David Voduc, Dongsheng Tu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 12, 2008
Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17J N Ingle, D Tu, J L Pater, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 15, 2013
An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphomaA E Hay, B Klimm, B E Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2016
Fc-γ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal CancerGeoffrey Liu, Dongsheng Tu, Marcia Lewis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 2023
Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast CancerPamela J Goodwin, Bingshu E Chen, Karen A Gelmon, et al.
Pageof 73

Showing results (681-690 of 726) with videos related to

Sort By:
Pageof 73
JNCI Cancer Spectrum|September 6, 2021
Cancer Antigen 15-3/Mucin 1 Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs PlaceboPamela J Goodwin, Ryan J O Dowling, Marguerite Ennis, et al.
AIDS (London, England)|August 9, 2013
Higher rates of AIDS during the first year of antiretroviral therapy among migrants: the importance of tuberculosis, Bryan E Shepherd, Cathy A Jenkins, et al.
The Journal of Biological Chemistry|June 13, 2014
Insight into the architecture of the NuRD complex: structure of the RbAp48-MTA1 subcomplexSaad S M Alqarni, Andal Murthy, Wei Zhang, et al.
Journal of the International AIDS Society|March 22, 2016
Health outcomes among HIV-positive Latinos initiating antiretroviral therapy in North America versus Central and South AmericaCarina Cesar, John R Koethe, Mark J Giganti, et al.
Journal of the National Cancer Institute|July 2, 2013
Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarkerDennis C Sgroi, Erin Carney, Elizabeth Zarrella, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2012
Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trialMaggie C U Cheang, K David Voduc, Dongsheng Tu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 12, 2008
Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17J N Ingle, D Tu, J L Pater, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 15, 2013
An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphomaA E Hay, B Klimm, B E Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2016
Fc-γ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal CancerGeoffrey Liu, Dongsheng Tu, Marcia Lewis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 2023
Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast CancerPamela J Goodwin, Bingshu E Chen, Karen A Gelmon, et al.
Pageof 73